Appili Therapeutics Inc. (APLI.TO)
| Previous Close | 0.0350 |
| Open | 0.0350 |
| Bid | 0.0300 x N/A |
| Ask | 0.0350 x N/A |
| Day's Range | 0.0350 - 0.0350 |
| 52 Week Range | 0.0250 - 0.0800 |
| Volume | |
| Avg. Volume | 88,928 |
| Market Cap | 4.244M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
MOUNTAIN VIEW, Calif., August 29, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024.
- Business Wire
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
MOUNTAIN VIEW, Calif., August 21, 2024--Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had entered into a third amending agreement with Appili Therapeutics, Inc. (TSX: APLI; OTCPink: APLIF) ("Appili"), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential b
GlobeNewswireAppili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a third amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adiv
